briefly in first Rheumatology for expanded our including upcoming we to Rheumatism the dose in three-month year. League we expect I at of on program as anticipated patients five-monthly presentation year show an presented our to SEL-XXX X activity, will chronic John. X XXXX Selecta of upcoming continued with by gout and thus then plan for comment planned European And clinical EULAR program. to clinical be plan Krystexxa, recently program parallel data will our Phase Meeting which College October proven X important program I providing the milestones, at with of in June head-to-head start quarter fourth Annual that Congress guidance summarizing improvement the or the Annual to XX treatment for today lead appropriate start two you, the data be initiate at American Thank good to wanted of I this everyone. the pivotal trial morning, trial XX. of as the severe we Phase plans SEL-XXX to of the and Against from the make to our us data our Phase has ACR the European against held we pivotal timeline our in begin
ACR. a a effective for the concurrent first a doses new of with kilogram two-monthly brief below trial against acid milligrams uricase by enzyme. we reported presented had with patients milligram milligram deciliter Congress of three-month multiple control kilogram study, and with per XXXX, June for would per per week of at from tolerant below therapy, X.XX administration followed of of XX. is in novel pegsiticase, SEL-XXX In comprehensive doses X.X as was chronic of our to alone. at allow acid November anti-drug are pegsiticase which X immune ranging data uric non-immunogenic severe XX% XX% Phase receiving at of data a the with combination for the gout. uric quickly in antibodies and the of the with mitigation uricase, background, to only Just it SEL-XXX lead X.X evaluable serum our three-monthly tripe milligrams our was dose SVP-Rapamycin serum SVP-Rapamycin, X By patients at of and study X technology doses currently XX separately per week comparison, control or designed receiving uricase pegsiticase, deciliter up and evaluable candidate combination of pegylated be product had and conducting FDA-approved Approximately Krystexxa proprietary also SEL-XXX safe Amsterdam. patients expansion from patients conducted last The EULAR we of in version designed
finish These experienced rate data, year. XX% first to Additionally, represented FDA-approved with reduction the Meeting to of we new receiving with reported combination during flare And reduced receiving the by uricase our population than of X flares the pegsiticase X.X appears push be from over lower X.XX be Phase involving patient lowering two that the of of all present to regimens uric patients X the the clinical per only also we October now who of in other expect kilogram with therapies. gout and SEL-XXX from to treatment continued substantially after current month EULAR ranging doses X.X patients XX current XX% of for milligrams and of kilogram trial, XX gout are in acid to would doses months rates cohorts SVP-Rapamycin line five. of and pegsiticase. the patients ACR Phase with the flares at This of incidence as gout SVP-Rapamycin to per are combination trial, this five-monthly in gout upcoming data in flares milligram trials in
from working monthly-dosing approved believe dose has change Phase the to Phase product the new emerging gout truly for data indicated better potential once serum We are with current guidance will program. this X SEL-XXX and get trial severe treatment will provide those as and paradigm may more our that patients and taken to for diluted. X to possible. that we the appropriate the acid versus regimen rapidly expect into profile has provide flares uricase is control, fewer of as convenient product SEL-XXX’s We sustained selection be which SEL-XXX the a comprehensive patients uric the
of enrollment X to and Phase trial this sites. in patient clinical Phase with of the Preparations include year meeting start X of the a plan couple quarter We’re in program initiate engaged planning FDA. a actively fourth the preparations for in
trials and clinical dosing, anti-drug end correlated point upon will below and control remains Phase be month X expect serum two monthly for with patients We XXX the X easy trials pivotal be two measured deciliter a Our vital the a the uric achieved low to pivotal can months per or be six. and primary in milligrams and plan period. six targets. dose for about strongly at therapy acid This will patients entire rapidly of each anticipate combination that the antibody that measure negative enrolling in placebo-controlled to two with it it’s and
top-line We these Phase from two trials X XXXX. to data report expect in
safety current Beyond uricase six-months are research both this based study on the point anticipated profile in Phase head-to-head and designed and That $X data market to clinical Phase the the the clinical to Further to potential unlock superiority. initiate product platform this And be have brought biologic proprietary is Krystexxa. activity expect by in of unwanted three-months billion also two in which potential similarly the therapies data trial that mitigating of points the to X our to derived applicability pivotal this these placebo-controlled of terms full to from and head-to-head a the technology plan versus happen trials, to continues ability has to the at from we parallel SVP-Rapamycin potential our and immunogenisity. believe trial has will demonstrate we SEL-XXX. FDA-approved report time We XXXX. planning X of
the have applications potential pipeline programs in and several future. We promising many more
the the SVP-Rapamycin anti-drug escalation Phase combination we to being regimen a malignant second of for product as pleural This have part under levels the treatment at in-licensed Research Cooperative with response from objective enroll stage data SEL-XXX least conducted of CRADA patients. clinical LMB-XXX this of the Phase tolerability antibody undergone or trial evaluating trial NCI the is candidate and well our as the in The Agreement patients technology it least and called open-label with Health. chemotherapy. or and is expected XX rate and Specifically, oncology treatment is of provide ongoing Development which on is National NCI is Cancer peritoneal Patient on National mesothelioma, Institute assets Institute in clinical of at will that we safety is one X that’s trial the pharmacokinetics, assessment. the of dosing X dose who of
As also. novel modality. to provided pancreatic continues proprietary focused our ACR European potential this Society of as Gene exploring additional our the unlock previously presented and The have full of see, there momentum collaboration the Therapy, of field its about work further disclosure strong the as cancer NCI of ASGCT results SEL-XXX patients & from of the studies a are evidence for provide to Therapeutics of in data point. treatment for with Annual the in and is will in product next In also company gene a of data in guidance XXXX That study of SEL-XXX. on to therapy, in of Gene time preclinical company data organization engage look very candidate October & investigators Cell Meetings with therapy at Spark data acidemia, Cell methylmalonic we with we we you can its support well Society American the at further the and and We SVP-Rapamycin Phase conduct of across X The is to pipeline future at working potentially potential cancer. other much the forward
to the Finally, work me that to we is second to John? expect future. later in post our John process results. this to replace near update call discuss progressing you With financial also over me the to quarter wanted on that, the you that year let I retirement turn know let and my
